• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Investing

What next as Moderna finds support at $130?

by May 13, 2022
by May 13, 2022

Moderna Inc. (NASDAQ:MRNA) has been strong since it rolled out COVID-19 vaccines. The demand for vaccines has started to slow down. The current year’s sales are projected to decline. Investors need to know what to expect from a company that is perfectly rated for value, growth, and momentum.

COVID-19 vaccine is the most successful of Moderna’s products but not the only one. The company has continued research on other mRNA vaccines and drugs. Products in the company’s pipeline are at various stages of clinical research and success. We expect to hear more about new products from the company in the coming months.

A more important consideration is that Moderna may move to snap deals in mergers and acquisitions. The crash in valuations of biotechnology stocks after the COVID-19 rally creates opportunities for M&A. Moderna has $19.3 billion in cash that it could invest in deals.

Moderna technical analysis shows key support holds

Source – TradingView

Technically, Moderna is trading at a valuation of $130. The valuation is at an important support level. The intra-week lowest price was $119. This analysis considers that the support level of $130 is likely to hold. The stock is also likely to establish a consolidation pattern around $130. This analysis projects consolidations to be between $130 support and $160 resistance.

Summary

Moderna will record declining sales for COVID-19 vaccines. New products and possible mergers and acquisitions will power the next phase of growth. Moderna will consolidate between $130 and $160 in the meantime.

The post What next as Moderna finds support at $130? appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Will BioNtech sustain the $140 support level?
next post
Will Charter Communications rise from the oversold region?

Related Posts

Deere down 15% despite strong results: ‘I like...

May 20, 2022

Twitter stock won’t ‘fall a whole lot’ if...

May 20, 2022

Jablonski is bullish on Amazon: ‘a lot of...

May 20, 2022

Alibaba stock price outlook: Why BABA is a...

May 20, 2022

Deckers Outdoor opened 20% up on Friday: what...

May 20, 2022

Palo Alto Q3 results: ‘getting more interest from...

May 20, 2022

Expert opinion: JPMorgan stock down 30% isn’t ‘that...

May 19, 2022

S&P 500 falls again as bears push stocks...

May 19, 2022

Ross Stores shares tank 25% on Q1 results

May 19, 2022

Bill Nygren gives away his favourite financial stock

May 19, 2022

Recent Posts

  • Deere down 15% despite strong results: ‘I like it for long-term’

    May 20, 2022
  • Twitter stock won’t ‘fall a whole lot’ if Musk walks away

    May 20, 2022
  • Jablonski is bullish on Amazon: ‘a lot of the issues are resolvable’

    May 20, 2022
  • Alibaba stock price outlook: Why BABA is a bargain

    May 20, 2022
  • Superstitious Storytellers

    May 20, 2022
  • Deckers Outdoor opened 20% up on Friday: what happened?

    May 20, 2022

Editors’ Picks

  • 1

    2 Canadian marijuana stocks to keep a close eye on

    February 5, 2022
  • 2

    Nvidia Corporation earnings beat not sufficient to boost stock – Is it a good buy?

    February 18, 2022
  • 3

    The IMF Should Be Eliminated, Not Expanded

    October 12, 2021
  • 4

    Micron Technology shares are trading lower after-hours: here’s why

    September 29, 2021
  • 5

    Here’s what inflation might look like in 2022

    November 23, 2021
  • 6

    Is Clorox stock a good buy ahead of its fiscal Q1 2022 results?

    October 30, 2021
  • 7

    Vaccine Authoritarianism Explained

    November 6, 2021
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Categories

  • Economy (812)
  • Editor's Pick (310)
  • Investing (2,500)
  • Stock (10)
About Us Terms & Conditions Privacy Policy Email WhiteListing Contact Us

Disclaimer: Portfolioperformancetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick

Read alsox

Samsung merges its segments and replaces Chief...

December 7, 2021

Hold Ionis Pharmaceuticals as the share price...

April 5, 2022

Deliveroo share price jumped after forward guidance....

March 18, 2022